Compare Torrent Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs STERLING BIOTECH - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA STERLING BIOTECH TORRENT PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 59.6 -0.4 - View Chart
P/BV x 6.3 0.0 44,259.3% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
STERLING BIOTECH
Dec-13
TORRENT PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,55011 14,761.9%   
Low Rs1,1443 33,632.4%   
Sales per share (Unadj.) Rs354.726.8 1,323.1%  
Earnings per share (Unadj.) Rs40.1-15.0 -267.9%  
Cash flow per share (Unadj.) Rs64.2-5.5 -1,175.6%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.154.9 497.7%  
Shares outstanding (eoy) m169.22267.87 63.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.80.3 1,464.5%   
Avg P/E ratio x33.6-0.5 -7,232.3%  
P/CF ratio (eoy) x21.0-1.3 -1,648.3%  
Price / Book Value ratio x4.90.1 3,893.5%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8971,862 12,241.4%   
No. of employees `00014.71.4 1,085.7%   
Total wages/salary Rs m11,353547 2,076.2%   
Avg. sales/employee Rs Th4,083.05,303.3 77.0%   
Avg. wages/employee Rs Th772.3403.8 191.2%   
Avg. net profit/employee Rs Th461.3-2,959.0 -15.6%   
INCOME DATA
Net Sales Rs m60,0217,181 835.9%  
Other income Rs m2,98843 7,015.0%   
Total revenues Rs m63,0097,223 872.3%   
Gross profit Rs m13,493947 1,424.9%  
Depreciation Rs m4,0862,543 160.7%   
Interest Rs m3,0854,377 70.5%   
Profit before tax Rs m9,310-5,931 -157.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529-1,924 -131.4%   
Profit after tax Rs m6,781-4,007 -169.3%  
Gross profit margin %22.513.2 170.5%  
Effective tax rate %27.232.4 83.7%   
Net profit margin %11.3-55.8 -20.2%  
BALANCE SHEET DATA
Current assets Rs m52,62314,335 367.1%   
Current liabilities Rs m52,02249,809 104.4%   
Net working cap to sales %1.0-494.0 -0.2%  
Current ratio x1.00.3 351.5%  
Inventory Days Days120403 29.6%  
Debtors Days Days76171 44.7%  
Net fixed assets Rs m85,01655,432 153.4%   
Share capital Rs m846268 315.9%   
"Free" reserves Rs m45,37613,935 325.6%   
Net worth Rs m46,22214,701 314.4%   
Long term debt Rs m41,1159,478 433.8%   
Total assets Rs m142,43273,988 192.5%  
Interest coverage x4.0-0.4 -1,132.0%   
Debt to equity ratio x0.90.6 138.0%  
Sales to assets ratio x0.40.1 434.2%   
Return on assets %6.90.5 1,382.9%  
Return on equity %14.7-27.3 -53.8%  
Return on capital %14.2-6.4 -220.9%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m14,5801,860 784.0%   
Fx outflow Rs m3,60025 14,463.2%   
Net fx Rs m10,9801,835 598.4%   
CASH FLOW
From Operations Rs m8,9421,719 520.3%  
From Investments Rs m-47,070-3,148 1,495.1%  
From Financial Activity Rs m34,1741,426 2,396.5%  
Net Cashflow Rs m-3,655-3 107,500.0%  

Share Holding

Indian Promoters % 71.5 33.9 210.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.0 -  
FIIs % 12.6 9.9 127.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.8 39.3 22.4%  
Shareholders   26,511 21,482 123.4%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare TORRENT PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 13, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS